4D Molecular Therapeutics (FDMT)
Engineers virus-based gene therapies for eye and lung diseases, led by a late-stage retinal candidate.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 161.40% | 116.50M shares | |
|---|---|---|---|
| 166 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.20% | 864.8K shares | |
| 4 holders · as of Sep 22, 2026 | |||
| Strategic holders | 7.39% | 5.34M shares | |
| 2 holders · as of Apr 7, 2026 | |||
| Adds to | 169.99% | ||
72.18M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (72.18M in the company's Sep 23, 2026 report, 52.28M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 169.99%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
166 holders · 58.25M shares · 35 new positions · 95 increased · 39 reduced · 25 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 5.75M | 7.96% | +5.75Mnew | Aug 14, 2026 |
| Ra Capital Management, L.P. | 5.05M | 7.00% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 4.55M | 6.30% | +400.8K | Aug 7, 2026 |
| Goldman Sachs Group Inc | 4.26M | 5.90% | +53.2K | Aug 14, 2026 |
| Novo Holdings A/S | 3.25M | 4.50% | −401.6K | Aug 14, 2026 |
| State Street Corp | 2.91M | 4.03% | +203.2K | Aug 7, 2026 |
| BVF Inc/IL | 2.88M | 3.99% | 0 | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.51M | 3.48% | +2.51Mnew | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 10.30% | 5.25M | 13G | Apr 7, 2026 |
| RA Capital Management, L.P. | 9.90% | 5.11M | 13G | May 15, 2026 |
| The Goldman Sachs Group, Inc. | 7.50% | 4.29M | 13G | Feb 9, 2026 |
| Biotechnology Value Fund L P | 7.30% | 3.91M | 13G | May 15, 2026 |
| BlackRock, Inc. | 6.60% | 3.06M | 13G | Oct 17, 2025 |
| Novo Holdings A/S | 6.40% | 3.65M | 13G | Feb 17, 2026 |
| State Street Corporation | 5.30% | 2.71M | 13G | May 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 1,635 | $13.65 | 8,617 |
| Sep 14, 2026 | David Kirndirector, officer: See Remarks | Sale | 58,333 | $13.90 | 767,486 |
| Sep 1, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 584 | $14.00 | 8,617 |
| Aug 19, 2026 | David Kirndirector, officer: See Remarks | Sale · 2 lots | 69,076 | $15.75 | 825,819 |
| Aug 17, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 1,635 | $12.20 | 8,617 |
| Aug 13, 2026 | Scott Bizilyofficer: Chief Legal Officer | Sale | 1,635 | $12.00 | 8,617 |
| Aug 4, 2026 | David Kirndirector, officer: See Remarks | Sale | 26,842 | $10.23 | 844,895 |
| Aug 3, 2026 | David Kirndirector, officer: See Remarks | Sale | 12,415 | $10.05 | 871,737 |
| Jul 10, 2026 | David Kirndirector, officer: See Remarks | Sale · 2 lots | 15,725 | $12.03 | 884,152 |
| Jul 9, 2026 | David Kirndirector, officer: See Remarks | Sale | 42,608 | $12.87 | 899,877 |
House and Senate disclosures
Not reported.